The Treatment of Prednisone in Mild Diabetic Rats: Biochemical Parameters and Cell Response
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.2174/1871530319bb6191204130007 http://hdl.handle.net/11449/196952 |
Resumo: | Background: Limited studies have been canied out with prednisone (PRED) in treatment by glucose intolerant individuals, even in this model the animals presented low blood glucose levels at adulthood, by the high regenerative capacity of beta-cell. Objective: The aim was to evaluate the effects of the treatment of PRED in mild diabetes on biochemical and immunological biomarkers. Methods: Rats were randomly divided into four groups: control (C), treated control C+PRED (treatment of 1.25 mg/Kg/day PRED); diabetic DM (mild diabetes) and treated diabetic DM PRED (treatment with same dose as C+PRED group). Untreated groups received vehicle, adjusted volume to body weight. The treatment lasted 21 days and measured body weight, food and water intake, and glycemia weekly. In the 3rd week, the Oral Glucose Tolerance Test (OGTT) and the Insulin Tolerance Test (ITT) was performed. On the last day, the rats were killed and the blood was collected for biochemical analyzes, leukogram and imm.unoglobulin G levels. Results: There was a significant decrease in body weight in mild diabetes; however, the treatment in diabetic groups increased food intake, glycemia, and the number of total leukocytes, lymphocytes and neutrophils. On the other hand, it decreased the levels of triglycerides, high -density and very low density lipoproteins. In addition, diabetic groups showed glucose intolerance and mild insulin resistance, confirming that this model induces glucose intolerant in adult life. Conclusion: The results showed that the use of prednisone is not recommended for glucose intolerant individuals and should he replaced in order to not to aggravate this condition. |
id |
UNSP_eae5aede0eaa17bb2442f9712c146c14 |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/196952 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
The Treatment of Prednisone in Mild Diabetic Rats: Biochemical Parameters and Cell ResponseDiabetesglucocorticoidsglycometabolismimmunosuppressantlipometabolismprednisoneBackground: Limited studies have been canied out with prednisone (PRED) in treatment by glucose intolerant individuals, even in this model the animals presented low blood glucose levels at adulthood, by the high regenerative capacity of beta-cell. Objective: The aim was to evaluate the effects of the treatment of PRED in mild diabetes on biochemical and immunological biomarkers. Methods: Rats were randomly divided into four groups: control (C), treated control C+PRED (treatment of 1.25 mg/Kg/day PRED); diabetic DM (mild diabetes) and treated diabetic DM PRED (treatment with same dose as C+PRED group). Untreated groups received vehicle, adjusted volume to body weight. The treatment lasted 21 days and measured body weight, food and water intake, and glycemia weekly. In the 3rd week, the Oral Glucose Tolerance Test (OGTT) and the Insulin Tolerance Test (ITT) was performed. On the last day, the rats were killed and the blood was collected for biochemical analyzes, leukogram and imm.unoglobulin G levels. Results: There was a significant decrease in body weight in mild diabetes; however, the treatment in diabetic groups increased food intake, glycemia, and the number of total leukocytes, lymphocytes and neutrophils. On the other hand, it decreased the levels of triglycerides, high -density and very low density lipoproteins. In addition, diabetic groups showed glucose intolerance and mild insulin resistance, confirming that this model induces glucose intolerant in adult life. Conclusion: The results showed that the use of prednisone is not recommended for glucose intolerant individuals and should he replaced in order to not to aggravate this condition.Fundacao de Amparo a Pesquisa do Estado de Mato Grosso (FAPEMAT), Cuiaba, Brazil (2014-2016)Sao Paulo State Univ UNESP, Inst Biosci, Postgrad Program Pharmacol & Biotechnol, Botucatu, SP, BrazilUniv Sao Paulo, Fac Med Ribeirao Preto, Dept Physiol, Sao Paulo, BrazilFed Univ Mato Grosso UFMT, Inst Biol Sci & Hlth, Lab Syst Physiol & Reprod Toxicol, Barra Do Garcas, Mato Grosso, BrazilSao Paulo State Univ UNESP, Inst Biosci, Postgrad Program Pharmacol & Biotechnol, Botucatu, SP, BrazilFundacao de Amparo a Pesquisa do Estado de Mato Grosso (FAPEMAT), Cuiaba, Brazil (2014-2016): 002 - 004/2015Fundacao de Amparo a Pesquisa do Estado de Mato Grosso (FAPEMAT), Cuiaba, Brazil (2014-2016): 36016.541.21414.17082016Bentham Science Publ LtdUniversidade Estadual Paulista (Unesp)Universidade de São Paulo (USP)Universidade Federal de Mato Grosso do Sul (UFMS)Machado, Mariana P. R. [UNESP]Schavinski, Aline Z.Deluque, Amanda L.Volpato, Gustavo T.Campos, Kleber E.2020-12-10T20:01:26Z2020-12-10T20:01:26Z2020-01-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article797-805http://dx.doi.org/10.2174/1871530319bb6191204130007Endocrine Metabolic & Immune Disorders-drug Targets. Sharjah: Bentham Science Publ Ltd, v. 20, n. 5, p. 797-805, 2020.1871-5303http://hdl.handle.net/11449/19695210.2174/1871530319bb6191204130007WOS:000538153000016Web of Sciencereponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengEndocrine Metabolic & Immune Disorders-drug Targetsinfo:eu-repo/semantics/openAccess2021-10-23T10:11:21Zoai:repositorio.unesp.br:11449/196952Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T20:40:33.026853Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
The Treatment of Prednisone in Mild Diabetic Rats: Biochemical Parameters and Cell Response |
title |
The Treatment of Prednisone in Mild Diabetic Rats: Biochemical Parameters and Cell Response |
spellingShingle |
The Treatment of Prednisone in Mild Diabetic Rats: Biochemical Parameters and Cell Response Machado, Mariana P. R. [UNESP] Diabetes glucocorticoids glycometabolism immunosuppressant lipometabolism prednisone |
title_short |
The Treatment of Prednisone in Mild Diabetic Rats: Biochemical Parameters and Cell Response |
title_full |
The Treatment of Prednisone in Mild Diabetic Rats: Biochemical Parameters and Cell Response |
title_fullStr |
The Treatment of Prednisone in Mild Diabetic Rats: Biochemical Parameters and Cell Response |
title_full_unstemmed |
The Treatment of Prednisone in Mild Diabetic Rats: Biochemical Parameters and Cell Response |
title_sort |
The Treatment of Prednisone in Mild Diabetic Rats: Biochemical Parameters and Cell Response |
author |
Machado, Mariana P. R. [UNESP] |
author_facet |
Machado, Mariana P. R. [UNESP] Schavinski, Aline Z. Deluque, Amanda L. Volpato, Gustavo T. Campos, Kleber E. |
author_role |
author |
author2 |
Schavinski, Aline Z. Deluque, Amanda L. Volpato, Gustavo T. Campos, Kleber E. |
author2_role |
author author author author |
dc.contributor.none.fl_str_mv |
Universidade Estadual Paulista (Unesp) Universidade de São Paulo (USP) Universidade Federal de Mato Grosso do Sul (UFMS) |
dc.contributor.author.fl_str_mv |
Machado, Mariana P. R. [UNESP] Schavinski, Aline Z. Deluque, Amanda L. Volpato, Gustavo T. Campos, Kleber E. |
dc.subject.por.fl_str_mv |
Diabetes glucocorticoids glycometabolism immunosuppressant lipometabolism prednisone |
topic |
Diabetes glucocorticoids glycometabolism immunosuppressant lipometabolism prednisone |
description |
Background: Limited studies have been canied out with prednisone (PRED) in treatment by glucose intolerant individuals, even in this model the animals presented low blood glucose levels at adulthood, by the high regenerative capacity of beta-cell. Objective: The aim was to evaluate the effects of the treatment of PRED in mild diabetes on biochemical and immunological biomarkers. Methods: Rats were randomly divided into four groups: control (C), treated control C+PRED (treatment of 1.25 mg/Kg/day PRED); diabetic DM (mild diabetes) and treated diabetic DM PRED (treatment with same dose as C+PRED group). Untreated groups received vehicle, adjusted volume to body weight. The treatment lasted 21 days and measured body weight, food and water intake, and glycemia weekly. In the 3rd week, the Oral Glucose Tolerance Test (OGTT) and the Insulin Tolerance Test (ITT) was performed. On the last day, the rats were killed and the blood was collected for biochemical analyzes, leukogram and imm.unoglobulin G levels. Results: There was a significant decrease in body weight in mild diabetes; however, the treatment in diabetic groups increased food intake, glycemia, and the number of total leukocytes, lymphocytes and neutrophils. On the other hand, it decreased the levels of triglycerides, high -density and very low density lipoproteins. In addition, diabetic groups showed glucose intolerance and mild insulin resistance, confirming that this model induces glucose intolerant in adult life. Conclusion: The results showed that the use of prednisone is not recommended for glucose intolerant individuals and should he replaced in order to not to aggravate this condition. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-12-10T20:01:26Z 2020-12-10T20:01:26Z 2020-01-01 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.2174/1871530319bb6191204130007 Endocrine Metabolic & Immune Disorders-drug Targets. Sharjah: Bentham Science Publ Ltd, v. 20, n. 5, p. 797-805, 2020. 1871-5303 http://hdl.handle.net/11449/196952 10.2174/1871530319bb6191204130007 WOS:000538153000016 |
url |
http://dx.doi.org/10.2174/1871530319bb6191204130007 http://hdl.handle.net/11449/196952 |
identifier_str_mv |
Endocrine Metabolic & Immune Disorders-drug Targets. Sharjah: Bentham Science Publ Ltd, v. 20, n. 5, p. 797-805, 2020. 1871-5303 10.2174/1871530319bb6191204130007 WOS:000538153000016 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Endocrine Metabolic & Immune Disorders-drug Targets |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
797-805 |
dc.publisher.none.fl_str_mv |
Bentham Science Publ Ltd |
publisher.none.fl_str_mv |
Bentham Science Publ Ltd |
dc.source.none.fl_str_mv |
Web of Science reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808129233432608768 |